A Prospective, Single-center, One-arm Clinical Study of Apatinib Combined With Chemotherapy for Pretreated Patients With Advanced Small Cell Lung Cancer
- Sponsor
- The First Hospital of Jilin University
- Study ID
- NCT03547804
- Phase
- PHASE2
- Status
- Completed
Conditions
- Small-cell Lung Cancer
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 75 Years
- Healthy Volunteers
- Not accepted
Interventions
- Apatinib — DRUG500 mg qd/250mg
- chemotherapy — DRUGChemotherapeutic agents are limited to irinotecan or docetaxel alone.
Study Details
At present, with the increasing intensities of the tobacco industry and air pollution in China, the incidence and mortality of lung cancer have become the most important issue that threatens human health.Over the past two decades, the treatment of SCLC still stays in the mode of treatment based on radiotherapy and chemotherapy. This is a prospective, single-center, one-arm clinical study designed to evaluate the efficacy and safety of apatinib plus chemotherapy for second-line and above treatment of advanced SCLC. 30 patients will receive apatinib 500mg qd orally, if the patient has a grade 3/4 adverse reaction during apatinib treatment, it can be reduced to apatinib 250mg qd orally.The dose was later reduced from 500 mg to 250 mg per day based on a recommendation of the principal investigator to reduce the adverse events. Chemotherapeutic agents are limited to irinotecan or docetaxel alone.The primary outcome endpoint was progression-free survival
Key Dates
- Start date
- May 31, 2018
- Status verified
- Sep 2020
- Primary completion
- Oct 25, 2019
- Completion
- Sep 1, 2020
Study Design
- Enrollment
- 31 participants (actual)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: experimental armapatinib 500 mg qd;The dose was later reduced from 500 mg to 250 mg per day based on a recommendation of the principal investigator to reduce the adverse events.Chemotherapeutic agents are limited to irinotecan or docetaxel alone.
Primary Outcome Measure
PFS [ Time Frame: 1 year ]
Related Studies
- Prospective Study of Intensity-Modulated Proton Therapy (IMPT) for Small Cell Lung CancerRecruiting · Emory University · Atlanta, Georgia
- A Multicenter Cancer Biospecimen Collection StudyRecruiting · Cofactor Genomics, Inc. · San Francisco, California
- Durvalumab and Ablative Radiation in Small Cell Lung Cancer (DARES)PHASE2 · Recruiting · University of Chicago · Chicago, Illinois
- A Study of Stereotactic Radiosurgery (SRS) for People With Lung Cancer That Has Spread to the BrainPHASE2 · Recruiting · Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey